{'fraction_non_alphanumeric': 0.02857142857142857, 'fraction_numerical': 0.004285714285714286, 'mean_word_length': 5.805825242718447, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Detour on the Road to a Cure.

In the article that accompanies this editorial, Piccart-Gebhart and an international group of colleagues 1 report the results of the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) trial, a large multicenter—indeed, multicontinent—trial that investigated the benefits of adding the small-molecule receptor tyrosine kinase inhibitor lapatinib to trastuzumab in the adjuvant human epidermal growth factor receptor (HER)2–positive breast cancer setting. The results are important, and like many important results, they raise nearly as many questions as they answer.